您好,欢迎您

2024 EAU大会泌尿肿瘤重磅试验汇总,ADC、免疫、靶向、内分泌治疗仍是重点!

03月17日
编译:肿瘤资讯
来源:肿瘤资讯

2024年第39届欧洲泌尿外科协会年会(EAU24)将于当地时间4月5日至8日在法国巴黎盛大召开。作为欧洲最具影响力的泌尿外科学术会议,EAU24在国际泌尿外科学界的影响力非同凡响。


本期小编特别筛选2024 EAU摘要会议环节中泌尿肿瘤领域的最新重磅临床研究,涉及ADC、免疫、靶向、内分泌治疗等。


ADC类药物

A0094: Neoadjuvant disitamab vedotin combined with tislelizumab for locally advanced upper urinary tract carcinoma: A pilot study for a phase II trial

局部晚期上尿路尿路上皮癌患者接受维迪西妥单抗联合替雷利珠单抗新辅助治疗的初步研究:II期试验的试点研究


A0738: TRUCE04: A Phase II clinical trial of RC48 for High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) 24)

TRUCE04:维迪西妥单抗用于高风险非肌层浸润性膀胱癌的II期临床试验


A0746: Phase 3 study of disitamab vedotin with pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma that expresses HER2 (DV-001; trial in progress)
针对未经治疗的表达HER2的局部晚期或转移性尿路上皮癌患者,维迪西妥单抗联合帕博利珠单抗vs化疗的III期研究(DV-001;试验进行中)


A0539: Preclinical evidence for the use of anti-TROP-2 antibody-drug conjugate Sacituzumab govitecan in cerebral metastasized castration-resistant prostate cancer
抗TROP-2抗体药物偶联物Sacituzumab govitecan(SG)在脑转移去势抵抗性前列腺癌中的临床前证据


A1107: Enfortumab vedotin and pembrolizumab (EV+P) versus chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC): Results from the global phase 3 EV-302/KEYNOTE-A39 study
在未经治疗局部晚期或转移性尿路上皮癌中比较Enfortumab vedotin联合帕博利珠单抗(EV+P)与化疗:来自全球III期EV-302/KEYNOTE-A39研究的结果

免疫治疗

A0731: First results of the phase Ib-II BladderGATE clinical trial: intravenous atezolizumab + intravesical bacillus Calmette-Guérin (BCG) upfront combination in BCG-naïve high risk non-muscle invasive bladder cancer patients
Ib-II期BladderGATE试验的第一次结果:静脉注射阿替利珠单抗 +膀胱内卡介苗(BCG)预先联合治疗未经BCG治疗的高风险NMIBC


A0741: Intravesical administration of Durvalumab to patients with high risk non muscle invasive bladder cancer who experience BCG failure. Final results from a phase II study by the Hellenic GU Cancer Group
BCG失败的高风险NMIBC患者膀胱内给药度伐利尤单抗: 希腊GU癌症小组的II期研究的最终结果


A0838: Outcome of patients with synchronous metastatic renal cell carcinoma treated with nivolumab and ipilimumab and the primary tumour in place
接受纳武利尤单抗和伊匹木单抗治疗且原发肿瘤未切除的同步转移性肾细胞癌患者的结果


A0901: First results of NURE-Combo: A phase 2 study of neoadjuvant Nivolumab (NIVO) and Nab-Paclitaxel (ABX) followed by postsurgical adjuvant NIVO in patients (pts) with Muscle-Invasive Bladder Cancer (MIBC)
NURE-Combo的首次结果:一项II期研究,MIBC患者接受新辅助纳武利尤单抗和Nab-Paclitaxel(ABX)后辅助纳武利尤单抗的效果


A0904: Tislelizumab in combination with gemcitabine plus cisplatin as neoadjuvant therapy for lymph node‐positive bladder cancer: Results of a prospective study
替雷利珠单抗联合吉西他滨加顺铂作为淋巴结阳性膀胱癌的新辅助疗法:前瞻性研究结果

内分泌药物治疗

A0602: Three-year oncological outcomes of the randomized phase II trial ARNEO: Neoadjuvant degarelix with or without apalutamide prior to radical prostatectomy for high-risk prostate cancer

随机II期试验ARNEO的3年肿瘤学结局:高危前列腺癌根治性前列腺切除术前新辅助地加瑞克联合或不联合阿帕他胺


A0604: Two-year Quality of Life (QoL) outcomes of the randomized phase II trial ARNEO: Neoadjuvant degarelix with or without apalutamide prior to radical prostatectomy for high-risk prostate cance

随机II期试验ARNEO的2年生活质量结局:高危前列腺癌根治性前列腺切除术前新辅助新辅助地加瑞克联合或不联合阿帕他胺


A0645: Fracture-related hospitalisations in de novo advanced or metastatic hormone-sensitive prostate cancer: Secondary analysis of the STAMPEDE abiraterone acetate plus prednisone +/- enzalutamide and M1|RT phase 3 trials using health systems data

原发性晚期或转移性前列腺癌患者骨折相关住院治疗:STAMPEDE醋酸阿比特龙+泼尼松+/- 恩扎卢胺和M1的次要分析|使用卫生系统数据的RT III期试验 

靶向治疗

A0596: First safety and efficacy results of the TAR-210 erdafitinib intravesical delivery system in patients with non–muscle-invasive bladder cancer with select FGFR alterations

TAR-210 厄达替尼膀胱内给药系统在伴有特定FGFR突变的NMIBC患者中的首次安全性和疗效结果

           

A0613: Neoadjuvant pamiparib plus abiraterone and ADT for high-risk/very high-risk localized prostate cancer: Results of a prospective study

新辅助帕米帕尼联合阿比特龙和ADT治疗高危/极高危局限性前列腺癌:前瞻性研究结果    


A0839: Papillary Renal Cell Carcinoma (pRCC): Outcomes of patients receiving first-line immune-based combinations or Tyrosine Kinase Inhibitors (TKIs) from the ARON-1 study

乳头状肾细胞癌(pRCC):ARON-1研究中接受基于免疫的一线联合治疗或酪氨酸激酶抑制剂(TKI)治疗的患者的结局

参考文献

https://urosource.uroweb.org/resource-centres/EAU24/search?event=EAU24&resourceType=Abstract.



责任编辑:肿瘤资讯-CY
排版编辑:肿瘤资讯-CY



评论
03月18日
蒋从飞
响水县人民医院 | 肿瘤科
内容丰富,收获满满。
03月18日
陈清
衢州市柯城区人民医院 | 血液肿瘤科
好好学习,天天向上!
03月18日
雷昕奕
永州市中心医院 | 胃肠外科
泌尿系肿瘤重磅实验。